Skip to content

Compare medicines

Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.

Attribute
In shortBreast cancer hormone therapy after menopause; also a fertility drug.Aromatase inhibitor for breast cancer treatment and prevention.
Body systemCancerCancer
Drug classAromatase inhibitorsAromatase inhibitors
SupplyPrescription onlyWHO essential medicinePrescription onlyWHO essential medicine
Main usesHormone-receptor-positive breast cancer after menopause, Ovulation induction in PCOS (off-label)Breast cancer after menopause, Breast cancer prevention (high risk)
How it worksShuts down oestrogen production after menopause.Cuts oestrogen levels after menopause.
Starts working——
Half-lifeAbout 2 daysAbout 50 hours
Typical adult doseBreast cancer: 2.5 mg once a day for 5–10 years.1 mg once a day.
FormsTabletTablet
Common side effectsJoint and muscle pain, Hot flushes, Fatigue, Raised cholesterolHot flushes, Joint pain, Tiredness
Serious side effectsBone loss and fractures, Heart problems (rare)Bone thinning, Severe skin reactions (rare)
Don't take if——
Alcohol——
PregnancyUsually avoidedContraindicated in pregnancy (fertility use is before conception).Usually avoidedNot for use in pregnancy.
Breastfeeding——
In use since19961995
Brand namesUnited States: FemaraUnited Kingdom: FemaraIndia: Letroz, Femara, LetovalUnited States: ArimidexUnited Kingdom: ArimidexIndia: Armotraz, Altraz
Legal status——
ATC codeL02BG04L02BG03

Taken together

No interaction between these medicines is recorded in the atlas.

Open in the interaction checker